Eli Lilly and Company has entered into an agreement with Starpharma Holdings Limited, under which Lilly will apply Starpharma's dendrimer drug delivery technology to enhance compounds in its human pharmaceutical portfolio.
Starpharma is an Australia-based developer of nanotechnology products, while Lilly is a US-based pharmaceutical company.
Under the terms of the agreement, Lilly will fund a collaborative research and development program with the aim of creating improved drugs incorporating Starpharma's proprietary delivery technology, to be commercialized by Lilly.
Starpharma Holdings Limited is a world leader in the development of nanotechnology products for pharmaceutical, life-science and other applications.
Starpharma’s lead product is VivaGel®, a gel-based formulation of a nano-pharmaceutical under development as a vaginal microbicide to prevent the transmission of sexually transmitted infections, including HIV and genital herpes.
VivaGel® is at the expanded safety/Phase IIa stage of clinical development. VivaGel® has been granted Fast Track status by the US Food and Drug Administration (FDA), which will accelerate the clinical and regulatory process. In addition, VivaGel® has been awarded US$20.3 million by the National Institutes of Health (NIH) to progress the development for HIV. The NIH has provided additional funding to develop VivaGel® against genital herpes.
Starpharma has a 100% owned US-based subsidiary Dendritic Nanotechnologies Inc (DNT) expanding the company’s potential products to include drug delivery and industrial specialty chemical applications, many of which have near-term cash-flow opportunities.
Starpharma’s lead product is VivaGel®, a gel-based formulation of a nano-pharmaceutical under development as a vaginal microbicide to prevent the transmission of sexually transmitted infections, including HIV and genital herpes.
VivaGel® is at the expanded safety/Phase IIa stage of clinical development. VivaGel® has been granted Fast Track status by the US Food and Drug Administration (FDA), which will accelerate the clinical and regulatory process. In addition, VivaGel® has been awarded US$20.3 million by the National Institutes of Health (NIH) to progress the development for HIV. The NIH has provided additional funding to develop VivaGel® against genital herpes.
Starpharma has a 100% owned US-based subsidiary Dendritic Nanotechnologies Inc (DNT) expanding the company’s potential products to include drug delivery and industrial specialty chemical applications, many of which have near-term cash-flow opportunities.
About Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.
About Starpharma
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer technology for pharmaceutical, life-science and other applications. Products based on SPL’s dendrimer technology are already on the market in the form
In the pharmaceutical field Starpharma is developing VivaGel® as a vaginal microbicide and condom coating and has specific programs in the areas of Drug Delivery and Drug Optimisation technologies (using dendrimers to control where and when drugs go when introduced to the body) and Diagnostics. More broadly the company is exploring dendrimer opportunities in materials science applications including water remediation.
No comments:
Post a Comment